<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2014-445-450</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-1968</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Вопросы качества жизни в комплексном обследовании пациентов с системной красной волчанкой</article-title><trans-title-group xml:lang="en"><trans-title>QUALITY-OF-LIFE ISSUES IN THE COMPREHENSIVE EXAMINATION OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абишева</surname><given-names>C. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Abisheva</surname><given-names>S. T.</given-names></name></name-alternatives><email xlink:type="simple">saule_tabisheva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сарманова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sarmanova</surname><given-names>A. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>АО «Медицинский  университет Астана»,Астана, Казахстан</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical University of Astana, Astana, Kazakhstan</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>АО «Медицинский университет Астана», Астана, Казахстан</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical University of Astana, Astana, Kazakhstan</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2014</year></pub-date><volume>52</volume><issue>4</issue><fpage>445</fpage><lpage>450</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Абишева C.Т., Сарманова А.А., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Абишева C.Т., Сарманова А.А.</copyright-holder><copyright-holder xml:lang="en">Abisheva S.T., Sarmanova A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/1968">https://rsp.mediar-press.net/rsp/article/view/1968</self-uri><abstract><p>Системная красная волчанка (СКВ) находится в центре внимания современных исследователей в течение многих лет ввиду хронического прогредиентного течения болезни с зачастую необратимым поражением различных органов и систем, высокого уровня смертности. Несмотря на значительные успехи в диагностике и терапии СКВ, обеспечившие увеличение продолжительности жизни, качество жизни больных остается ниже популяционного уровня. В настоящее время качество жизни наряду с другими параметрами рекомендуется учитывать при проведении комплексного обследования больных СКВ.</p></abstract><trans-abstract xml:lang="en"><p>Systemic lupus erythematosus (SLE) has been a central preoccupation of modern-day investigators for many years due to the chronic progressive course of the disease with frequently irreversible involvement of different organs and systems and to high death rates. Despite the notable advance made in the diagnosis and therapy of SLE, which has ensured longer survival, the quality of life in patients remains worse than the population level. At the moment, quality of life along with other parameters should be taken into account when comprehensively examining the patients with SLE.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматология</kwd><kwd>системная красная волчанка</kwd><kwd>качество жизни</kwd><kwd>SF-36</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatology</kwd><kwd>systemic lupus erythematosus</kwd><kwd>quality of life</kwd><kwd>SF-36</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2011. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical recommendations]. 2nd ed. Moscow: GEOTAR-Media; 2011. 752 p.]</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2011. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical recommendations]. 2nd ed. Moscow: GEOTAR-Media; 2011. 752 p.]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бадокин ВВ, редактор. Ревматология. Клинические лекции. Москва: Литтерра; 2012. 592 с. [Badokin VV, editor. Revmatologiya. Klinicheskie lektsii [Rheumatology. Clinical lectures]. Moscow: Litterra; 2012. 592 p.]</mixed-citation><mixed-citation xml:lang="en">Бадокин ВВ, редактор. Ревматология. Клинические лекции. Москва: Литтерра; 2012. 592 с. [Badokin VV, editor. Revmatologiya. Klinicheskie lektsii [Rheumatology. Clinical lectures]. Moscow: Litterra; 2012. 592 p.]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kind P, Williams A. Measuring success in health care – the time has come to do it properly. Health Policy Matter. 2004;(9):1–8.</mixed-citation><mixed-citation xml:lang="en">Kind P, Williams A. Measuring success in health care – the time has come to do it properly. Health Policy Matter. 2004;(9):1–8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Strand V, Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000;9(5):322–7. DOI: http://dx.doi.org/10.1191/096120300678828424.</mixed-citation><mixed-citation xml:lang="en">Strand V, Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000;9(5):322–7. DOI: http://dx.doi.org/10.1191/096120300678828424.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol. 2010;37(2):296–304. DOI: http://dx.doi.org/10.3899/jrheum.090778.</mixed-citation><mixed-citation xml:lang="en">Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol. 2010;37(2):296–304. DOI: http://dx.doi.org/10.3899/jrheum.090778.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10):633–43. DOI: http://dx.doi.org/10.1177/0961203306071710.</mixed-citation><mixed-citation xml:lang="en">McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10):633–43. DOI: http://dx.doi.org/10.1177/0961203306071710.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(8):1608–14.</mixed-citation><mixed-citation xml:lang="en">Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(8):1608–14.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Marx C, Mö rgeli HP, Bü chi S, Stoll T. Are there associations of health status, disease activity and damage in SLE patients? Results of a study of a cohort of a Swiss specialized outpatient clinic. Praxis (Bern 1994). 2007; 96(22):895–9. DOI: http://dx.doi.org/10.1024/1661-8157.96.22.895.</mixed-citation><mixed-citation xml:lang="en">Marx C, Mö rgeli HP, Bü chi S, Stoll T. Are there associations of health status, disease activity and damage in SLE patients? Results of a study of a cohort of a Swiss specialized outpatient clinic. Praxis (Bern 1994). 2007; 96(22):895–9. DOI: http://dx.doi.org/10.1024/1661-8157.96.22.895.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sutcliffe N, Clarke AE, Levinton C, et al. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol. 1999;26(11):2352–6.</mixed-citation><mixed-citation xml:lang="en">Sutcliffe N, Clarke AE, Levinton C, et al. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol. 1999;26(11):2352–6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dobkin PL, DaCosta D, Dritsa M, et al. Quality of life in systemic lupus erythematosus patients during more or less active disease states: differential contributors to mental and physical health. Arthritis Care Res. 1999;12(6):401–10. DOI: http://dx.doi.org/10.1002/1529-131(199912)12:6%3C401::AIDART8%3E3.0.CO;2-F.</mixed-citation><mixed-citation xml:lang="en">Dobkin PL, DaCosta D, Dritsa M, et al. Quality of life in systemic lupus erythematosus patients during more or less active disease states: differential contributors to mental and physical health. Arthritis Care Res. 1999;12(6):401–10. DOI: http://dx.doi.org/10.1002/1529-131(199912)12:6%3C401::AIDART8%3E3.0.CO;2-F.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Saba J, Quinet RJ, Davis WE, et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine. 2003;70(5):348–51. DOI: http://dx.doi.org/10.1016/S1297-319X(03)00065-4.</mixed-citation><mixed-citation xml:lang="en">Saba J, Quinet RJ, Davis WE, et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine. 2003;70(5):348–51. DOI: http://dx.doi.org/10.1016/S1297-319X(03)00065-4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kulczycka L, Sysa-Jedrzejowska A, Robak E. Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol. 2010;29(9):991–7. DOI:http://dx.doi.org/10.1007/s10067-010-1509-0.</mixed-citation><mixed-citation xml:lang="en">Kulczycka L, Sysa-Jedrzejowska A, Robak E. Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol. 2010;29(9):991–7. DOI:http://dx.doi.org/10.1007/s10067-010-1509-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus. 1998;7(2):101–7. DOI: http://dx.doi.org/10.1191/096120398678919813.</mixed-citation><mixed-citation xml:lang="en">Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus. 1998;7(2):101–7. DOI: http://dx.doi.org/10.1191/096120398678919813.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wilke CT, Jolly M, Block JA, et al. Ability of SF-36 and EQ-5D to discriminate among disease activity levels in lupus. Value in Health. 2007;10(3):15. DOI: http://dx.doi.org/10.1016/S1098- 3015(10)68578-6.</mixed-citation><mixed-citation xml:lang="en">Wilke CT, Jolly M, Block JA, et al. Ability of SF-36 and EQ-5D to discriminate among disease activity levels in lupus. Value in Health. 2007;10(3):15. DOI: http://dx.doi.org/10.1016/S1098- 3015(10)68578-6.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2004;43(12):1536–40. DOI: http://dx.doi.org/10.1093/rheumatology/keh376. Epub 2004 Sep 1.</mixed-citation><mixed-citation xml:lang="en">Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2004;43(12):1536–40. DOI: http://dx.doi.org/10.1093/rheumatology/keh376. Epub 2004 Sep 1.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2007:26(1):24–9. DOI: http://dx.doi.org/10.1007/s10067-006-0215-4.</mixed-citation><mixed-citation xml:lang="en">Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2007:26(1):24–9. DOI: http://dx.doi.org/10.1007/s10067-006-0215-4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Карпенко ЮЮ. Патология внутренних органов при поздней стадии системной красной волчанки (по данным регионарного регистра). Дисс. …. канд. мед. наук. Воронеж; 2008. [Karpenko YuYu. Patologiya vnutrennikh organov pri pozdnei stadii sistemnoi krasnoi volchanki (po dannym egionarnogo registra). Diss. …. kand. med. nauk [Pathology of an internal at a late stage of a systemic lupus erythematosus (according to the regionarny register); Dr. Diss. (Med. Sci.)].Voronezh; 2008.</mixed-citation><mixed-citation xml:lang="en">Карпенко ЮЮ. Патология внутренних органов при поздней стадии системной красной волчанки (по данным регионарного регистра). Дисс. …. канд. мед. наук. Воронеж; 2008. [Karpenko YuYu. Patologiya vnutrennikh organov pri pozdnei stadii sistemnoi krasnoi volchanki (po dannym egionarnogo registra). Diss. …. kand. med. nauk [Pathology of an internal at a late stage of a systemic lupus erythematosus (according to the regionarny register); Dr. Diss. (Med. Sci.)].Voronezh; 2008.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Асеева ЕА, Амирджанова ВН, Лисицына ТА, Завальская МВ. Качество жизни у больных системной красной волчанкой. Научно-практическая ревматология. 2013;51(3):324–31. [Aseeva EA, Amirdzhanova VN, Lisitsyna TA, Zaval'skaya MV. Quality of life in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practiсе. 2013;51(3):324–31. (In Russ.). DOI: http://dx.doi.org/10.14412/1995-4484-2013-1508.</mixed-citation><mixed-citation xml:lang="en">Асеева ЕА, Амирджанова ВН, Лисицына ТА, Завальская МВ. Качество жизни у больных системной красной волчанкой. Научно-практическая ревматология. 2013;51(3):324–31. [Aseeva EA, Amirdzhanova VN, Lisitsyna TA, Zaval'skaya MV. Quality of life in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practiсе. 2013;51(3):324–31. (In Russ.). DOI: http://dx.doi.org/10.14412/1995-4484-2013-1508.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Moldovan I, Katsaros E, Carr FN, et al. The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in healthrelated quality of life in a Southern California lupus cohort. Lupus. 2011;20(12):1285–92. DOI: http://dx.doi.org/10.1177/0961203311412097.</mixed-citation><mixed-citation xml:lang="en">Moldovan I, Katsaros E, Carr FN, et al. The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in healthrelated quality of life in a Southern California lupus cohort. Lupus. 2011;20(12):1285–92. DOI: http://dx.doi.org/10.1177/0961203311412097.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Alarcon GS, McGwin G Jr, Uribe A, et al. Systemic Lupus Erythematosus in a Multiethnic Lupus Cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 2004;51(3):465–74. DOI: http://dx.doi.org/10.1002/art.20409.</mixed-citation><mixed-citation xml:lang="en">Alarcon GS, McGwin G Jr, Uribe A, et al. Systemic Lupus Erythematosus in a Multiethnic Lupus Cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 2004;51(3):465–74. DOI: http://dx.doi.org/10.1002/art.20409.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Urowitz MB, Ong A, et al. Lack of correlation among 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol. 1996;14(3):305–8.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Urowitz MB, Ong A, et al. Lack of correlation among 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol. 1996;14(3):305–8.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Thumboo J, Fong KY, Ng T-P, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol. 1999;26(1):97–102.</mixed-citation><mixed-citation xml:lang="en">Thumboo J, Fong KY, Ng T-P, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol. 1999;26(1):97–102.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol. 1997;24(11):2145–8.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol. 1997;24(11):2145–8.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Hanly JG. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross-sectional study. Lupus. 1997;6(3):243–7. DOI: http://dx.doi.org/10.1177/096120339700600305.</mixed-citation><mixed-citation xml:lang="en">Hanly JG. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross-sectional study. Lupus. 1997;6(3):243–7. DOI: http://dx.doi.org/10.1177/096120339700600305.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Gilboe IM, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J Rheumatol. 1999;26(8):1694–700.</mixed-citation><mixed-citation xml:lang="en">Gilboe IM, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J Rheumatol. 1999;26(8):1694–700.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman AW, Alarcon GS, McGwin GJr, et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Care Res. 1999;12(4):256–66. DOI: http://dx.doi.org/10.1002/1529-0131(199908)12:4%3C256::AIDART4% 3E3.0.CO;2-G.</mixed-citation><mixed-citation xml:lang="en">Friedman AW, Alarcon GS, McGwin GJr, et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Care Res. 1999;12(4):256–66. DOI: http://dx.doi.org/10.1002/1529-0131(199908)12:4%3C256::AIDART4% 3E3.0.CO;2-G.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Thumboo J, Feng PH, Soh CH, et al. Validation of a Chinese version of the medical outcomes study family and marital functioning measures in patients with SLE. Lupus. 2000;9(9):702–7. DOI: http://dx.doi.org/10.1191/096120300666529212.</mixed-citation><mixed-citation xml:lang="en">Thumboo J, Feng PH, Soh CH, et al. Validation of a Chinese version of the medical outcomes study family and marital functioning measures in patients with SLE. Lupus. 2000;9(9):702–7. DOI: http://dx.doi.org/10.1191/096120300666529212.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Doria A, Rinaldi S, Ermani1 M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford). 2004;43(12):1580–6. Epub 2004 Sep 14.</mixed-citation><mixed-citation xml:lang="en">Doria A, Rinaldi S, Ermani1 M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford). 2004;43(12):1580–6. Epub 2004 Sep 14.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Freire EA, Maia IO, Nepomuceno JC, Ciconelli RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheumatol. 2007;26(3):423–8. DOI:http://dx.doi.org/10.1007/s10067-006-0517-6.</mixed-citation><mixed-citation xml:lang="en">Freire EA, Maia IO, Nepomuceno JC, Ciconelli RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheumatol. 2007;26(3):423–8. DOI:http://dx.doi.org/10.1007/s10067-006-0517-6.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kuriya B, Gladman DD, Ibanez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Care Res. 2008;59(2):181–5. DOI: http://dx.doi.org/10.1002/art.23339.</mixed-citation><mixed-citation xml:lang="en">Kuriya B, Gladman DD, Ibanez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Care Res. 2008;59(2):181–5. DOI: http://dx.doi.org/10.1002/art.23339.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol. 2009;38(2):121–7. DOI: http://dx.doi.org/10.1080/03009740802415527.</mixed-citation><mixed-citation xml:lang="en">Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol. 2009;38(2):121–7. DOI: http://dx.doi.org/10.1080/03009740802415527.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16. DOI:http://dx.doi.org/10.3899/jrheum.081022.</mixed-citation><mixed-citation xml:lang="en">Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16. DOI:http://dx.doi.org/10.3899/jrheum.081022.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Duarte C, Abreu P, Couto M, et al. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage. Acta Reumatol Port. 2010;35(1):30–5.</mixed-citation><mixed-citation xml:lang="en">Duarte C, Abreu P, Couto M, et al. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage. Acta Reumatol Port. 2010;35(1):30–5.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman D, Urowitz M, Fortin P, et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol.1996;23(11):1953–5.</mixed-citation><mixed-citation xml:lang="en">Gladman D, Urowitz M, Fortin P, et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol.1996;23(11):1953–5.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Strand V, Chu AD. Generic versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. J Rheumatol. 2011;38(9):1821–3. DOI: 10.3899/jrheum.110766.</mixed-citation><mixed-citation xml:lang="en">Strand V, Chu AD. Generic versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. J Rheumatol. 2011;38(9):1821–3. DOI: 10.3899/jrheum.110766.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Touma Z, Gladman DD, Ibanez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol. 2011;38(9):1898–905. DOI: http://dx.doi.org/10.3899/jrheum.110007.</mixed-citation><mixed-citation xml:lang="en">Touma Z, Gladman DD, Ibanez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol. 2011;38(9):1898–905. DOI: http://dx.doi.org/10.3899/jrheum.110007.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Yazdany J. Health-related quality of life measurement in systemic lupus erythematosus: The LupusQoL, SLEQoL, and L-QoL. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S413–9. DOI: 10.1002/acr.20636.</mixed-citation><mixed-citation xml:lang="en">Yazdany J. Health-related quality of life measurement in systemic lupus erythematosus: The LupusQoL, SLEQoL, and L-QoL. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S413–9. DOI: 10.1002/acr.20636.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific qualityof-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44(10):1267–76. DOI: http://dx.doi.org/10.1093/rheumatology/keh605.</mixed-citation><mixed-citation xml:lang="en">Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific qualityof-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44(10):1267–76. DOI: http://dx.doi.org/10.1093/rheumatology/keh605.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Conti F, Perricone C, Reboldi G, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014;23(8):743–51. DOI: http://dx.doi.org/10.1177/0961203314524466.</mixed-citation><mixed-citation xml:lang="en">Conti F, Perricone C, Reboldi G, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014;23(8):743–51. DOI: http://dx.doi.org/10.1177/0961203314524466.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">McElhone K, Castelino M, Abbott J, et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(11):2273–9. DOI: http://dx.doi.org/10.3899/jrheum.091277.</mixed-citation><mixed-citation xml:lang="en">McElhone K, Castelino M, Abbott J, et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(11):2273–9. DOI: http://dx.doi.org/10.3899/jrheum.091277.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Carrasco M, Mendoza-Pinto C, Cardiel MH, et al. Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL. Lupus. 2012;21(11):1219–24. DOI: http://dx.doi.org/10.1177/0961203312456749.</mixed-citation><mixed-citation xml:lang="en">Garcia-Carrasco M, Mendoza-Pinto C, Cardiel MH, et al. Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL. Lupus. 2012;21(11):1219–24. DOI: http://dx.doi.org/10.1177/0961203312456749.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Castelino M, Abbott J, McElhone K, Teh LS. Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford). 2013;52(4):684–96. DOI: http://dx.doi.org/10.1093/rheumatology/kes370.</mixed-citation><mixed-citation xml:lang="en">Castelino M, Abbott J, McElhone K, Teh LS. Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford). 2013;52(4):684–96. DOI: http://dx.doi.org/10.1093/rheumatology/kes370.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Stoll T, Stucki G, Malik J, et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(2):309–13.</mixed-citation><mixed-citation xml:lang="en">Stoll T, Stucki G, Malik J, et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(2):309–13.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Medeiros MM, Menezes AP, Silveira VA, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008;19(2):122–8. DOI: http://dx.doi.org/10.1016/j.ejim.2007.06.012.</mixed-citation><mixed-citation xml:lang="en">Medeiros MM, Menezes AP, Silveira VA, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008;19(2):122–8. DOI: http://dx.doi.org/10.1016/j.ejim.2007.06.012.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Hanly JG, Urowitz MB, Jackson D, et al. Systemic Lupus International Collaborating Clinics (SLICC). SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(6):961–7. DOI: http://dx.doi.org/10.1136/ard.2010.138792.</mixed-citation><mixed-citation xml:lang="en">Hanly JG, Urowitz MB, Jackson D, et al. Systemic Lupus International Collaborating Clinics (SLICC). SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(6):961–7. DOI: http://dx.doi.org/10.1136/ard.2010.138792.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol. 2009;36(5):947–52. DOI:http://dx.doi.org/10.3899/jrheum.080822.</mixed-citation><mixed-citation xml:lang="en">Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol. 2009;36(5):947–52. DOI:http://dx.doi.org/10.3899/jrheum.080822.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Чугунная СМ. Патология легких у больных системной красной волчанкой (клинические, инструментальные и биохимические аспекты). Дисс. … канд. мед. наук, Москва; 2005. [Chugunnaya SM. Patologiya legkikh u bol'nykh sistemnoi krasnoi volchankoi (klinicheskie, instrumental'nye i biokhimicheskie aspekty). Diss. … kand. med. nauk [Pathology of lungs at patients with a systemic lupus erythematosus (clinical, tool and biochemical aspects): Dr. Diss. (Med. Sci.)]. Moscow; 2005.]</mixed-citation><mixed-citation xml:lang="en">Чугунная СМ. Патология легких у больных системной красной волчанкой (клинические, инструментальные и биохимические аспекты). Дисс. … канд. мед. наук, Москва; 2005. [Chugunnaya SM. Patologiya legkikh u bol'nykh sistemnoi krasnoi volchankoi (klinicheskie, instrumental'nye i biokhimicheskie aspekty). Diss. … kand. med. nauk [Pathology of lungs at patients with a systemic lupus erythematosus (clinical, tool and biochemical aspects): Dr. Diss. (Med. Sci.)]. Moscow; 2005.]</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Pettersson S, Lovgren M, Eriksson LE, et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol. 2012;41(5):383–90. DOI: http://dx.doi.org/10.3109/03009742.2012.677857.</mixed-citation><mixed-citation xml:lang="en">Pettersson S, Lovgren M, Eriksson LE, et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol. 2012;41(5):383–90. DOI: http://dx.doi.org/10.3109/03009742.2012.677857.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Федоренко ДА. Синдром генерализованной слабости и его влияние на параметры качества жизни у больных некоторыми системными заболеваниями соединительной ткани. Дисс. … канд. мед. наук. Санкт-Петербург; 2004. [Fedorenko DA. Sindrom generalizovannoi slabosti i ego vliyanie na parametry kachestva zhizni u bol'nykh nekotorymi sistemnymi zabolevaniyami soedinitel'noi tkani. Diss. … kand. med. nauk [Syndrome of generalized weakness and its influence on parameters of quality of life at patients with some system diseases of connecting fabric: Dr. Diss. (Med. Sci.)]. Sankt-Peterburg; 2004.]</mixed-citation><mixed-citation xml:lang="en">Федоренко ДА. Синдром генерализованной слабости и его влияние на параметры качества жизни у больных некоторыми системными заболеваниями соединительной ткани. Дисс. … канд. мед. наук. Санкт-Петербург; 2004. [Fedorenko DA. Sindrom generalizovannoi slabosti i ego vliyanie na parametry kachestva zhizni u bol'nykh nekotorymi sistemnymi zabolevaniyami soedinitel'noi tkani. Diss. … kand. med. nauk [Syndrome of generalized weakness and its influence on parameters of quality of life at patients with some system diseases of connecting fabric: Dr. Diss. (Med. Sci.)]. Sankt-Peterburg; 2004.]</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Choi ST, Kang JI, Park IH, et al. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol. 2012;30(5):665–72.</mixed-citation><mixed-citation xml:lang="en">Choi ST, Kang JI, Park IH, et al. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol. 2012;30(5):665–72.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Navarrete-Navarrete N, Peralta-Ramirez MI, Sabio JM, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. DOI: 10.1177/0961203310378413. Epub 2010 Sep 14.</mixed-citation><mixed-citation xml:lang="en">Navarrete-Navarrete N, Peralta-Ramirez MI, Sabio JM, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. DOI: 10.1177/0961203310378413. Epub 2010 Sep 14.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Mak A, Tang CS, Ho RC. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus. 2013;22(3):254–61. DOI: http://dx.doi.org/10.1177/0961203312471872.</mixed-citation><mixed-citation xml:lang="en">Mak A, Tang CS, Ho RC. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus. 2013;22(3):254–61. DOI: http://dx.doi.org/10.1177/0961203312471872.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Daleboudt GM, Berger SP, Broadbent E, Kaptein AA. Healthrelated quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychol Health Med. 2011;16(4):393–404. DOI: 10.1080/13548506.2011.554566.</mixed-citation><mixed-citation xml:lang="en">Daleboudt GM, Berger SP, Broadbent E, Kaptein AA. Healthrelated quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychol Health Med. 2011;16(4):393–404. DOI: 10.1080/13548506.2011.554566.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Urowitz M, Gladman DD, Ibanez D, et al. Changes in quality of life in the first 5 years of disease in a multicentre cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014 Feb 4. DOI: 10.1002/acr.22299.</mixed-citation><mixed-citation xml:lang="en">Urowitz M, Gladman DD, Ibanez D, et al. Changes in quality of life in the first 5 years of disease in a multicentre cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014 Feb 4. DOI: 10.1002/acr.22299.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36(2):115–22.</mixed-citation><mixed-citation xml:lang="en">Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36(2):115–22.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Jolly M, Sandler DS, Sequeira W, Block JA. Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus. Arthritis Rheum. 2009;60(10):293.</mixed-citation><mixed-citation xml:lang="en">Jolly M, Sandler DS, Sequeira W, Block JA. Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus. Arthritis Rheum. 2009;60(10):293.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Berger SP, Broadbent E, Kaptein AA. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychology Health Med. 2011;16(4):393–404. DOI: 10.1080/13548506.2011.554566.</mixed-citation><mixed-citation xml:lang="en">Berger SP, Broadbent E, Kaptein AA. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychology Health Med. 2011;16(4):393–404. DOI: 10.1080/13548506.2011.554566.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Dussan KB, Magder L, Brodsky RA, et al. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17(12):1079–85. DOI: http://dx.doi.org/10.1177/0961203308093828.</mixed-citation><mixed-citation xml:lang="en">Dussan KB, Magder L, Brodsky RA, et al. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17(12):1079–85. DOI: http://dx.doi.org/10.1177/0961203308093828.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Grootscholten C, Snoek FJ, Bijl M, et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ ethylprednisolone in a randomized controlled trial. J Rheumatol. 2007;34(8):1699–707.</mixed-citation><mixed-citation xml:lang="en">Grootscholten C, Snoek FJ, Bijl M, et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ ethylprednisolone in a randomized controlled trial. J Rheumatol. 2007;34(8):1699–707.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Medeiros MM, Menezes AP, Silveira VA, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008 Mar;19(2):122–8. DOI: http://dx.doi.org/10.1016/j.ejim.2007.06.012.</mixed-citation><mixed-citation xml:lang="en">Medeiros MM, Menezes AP, Silveira VA, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008 Mar;19(2):122–8. DOI: http://dx.doi.org/10.1016/j.ejim.2007.06.012.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Tse KC, Tang CS, Lio WI, et al. Quality of life comparison between corticosteroid -and-mycofenolate mofetil and corticosteroid -and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;15(6):371–9. DOI: http://dx.doi.org/10.1191/0961203306lu2307xx.</mixed-citation><mixed-citation xml:lang="en">Tse KC, Tang CS, Lio WI, et al. Quality of life comparison between corticosteroid -and-mycofenolate mofetil and corticosteroid -and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;15(6):371–9. DOI: http://dx.doi.org/10.1191/0961203306lu2307xx.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson EC, Jayne DR, Dellow D, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as first line therapy in active lupus nephritis. Rheumatology (Oxford). 2007;46(7);1096–101. DOI: http://dx.doi.org/10.1093/rheumatology/kem054. Epub 2007 Apr 4.</mixed-citation><mixed-citation xml:lang="en">Wilson EC, Jayne DR, Dellow D, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as first line therapy in active lupus nephritis. Rheumatology (Oxford). 2007;46(7);1096–101. DOI: http://dx.doi.org/10.1093/rheumatology/kem054. Epub 2007 Apr 4.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Navarrete-Navarrete N, Peralta-Ramхirez MI, Sabio JM, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. DOI: 10.1177/0961203310378413. Epub 2010 Sep 14.</mixed-citation><mixed-citation xml:lang="en">Navarrete-Navarrete N, Peralta-Ramхirez MI, Sabio JM, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. DOI: 10.1177/0961203310378413. Epub 2010 Sep 14.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
